Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Change in Accured Expenses (2017 - 2025)

Historic Change in Accured Expenses for Cue Biopharma (CUE) over the last 9 years, with Q3 2025 value amounting to $352000.0.

  • Cue Biopharma's Change in Accured Expenses rose 12580.65% to $352000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 million, marking a year-over-year increase of 3088.92%. This contributed to the annual value of -$1.2 million for FY2024, which is 30901.36% down from last year.
  • Per Cue Biopharma's latest filing, its Change in Accured Expenses stood at $352000.0 for Q3 2025, which was up 12580.65% from -$2.7 million recorded in Q2 2025.
  • Cue Biopharma's 5-year Change in Accured Expenses high stood at $2.0 million for Q3 2021, and its period low was -$2.7 million during Q2 2025.
  • In the last 5 years, Cue Biopharma's Change in Accured Expenses had a median value of $27000.0 in 2021 and averaged -$48276.2.
  • As far as peak fluctuations go, Cue Biopharma's Change in Accured Expenses soared by 70392.16% in 2023, and later plummeted by 32046.51% in 2025.
  • Over the past 5 years, Cue Biopharma's Change in Accured Expenses (Quarter) stood at $630752.0 in 2021, then plummeted by 152.32% to -$330000.0 in 2022, then crashed by 198.48% to -$985000.0 in 2023, then skyrocketed by 70.46% to -$291000.0 in 2024, then skyrocketed by 220.96% to $352000.0 in 2025.
  • Its last three reported values are $352000.0 in Q3 2025, -$2.7 million for Q2 2025, and $1.3 million during Q1 2025.